http://orcid.org/0000-0001-7061-0101
Citations (19)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Mohammed Alluhidan, Hana Alabdulkarim, Ali Alrumaih, Abdulrahman Al-Turaiki, Abdullah Alshahrani, Saad Al-Qahtani, Abdulaziz Alhossan & Ahmed Al-Jedai. (2023) Budget impact of introducing oral semaglutide to the public healthcare benefit package in Saudi Arabia. Journal of Medical Economics 26:1, pages 1455-1468.
Read now
Read now
Articles from other publishers (18)
Reema R. Mody, Kellie L. Meyer, Jennifer M. Ward & Ken B. O’Day. (2023) Cost per Patient Achieving Treatment Targets and Number Needed to Treat with Tirzepatide Versus Semaglutide 1 mg in Patients with Type 2 Diabetes in the United States. Diabetes Therapy 14:12, pages 2045-2055.
Crossref
Crossref
Monica Frazer, Caroline Swift, Andrew Sargent, Michael Leszko, Erin Buysman, Noelle N. Gronroos, Sara Alvarez, Tyler J. Dunn, Josh Noone & Cory L. Gamble. (2023) Real-world HbA1c changes and prescription characteristics among type 2 diabetes mellitus patients initiating treatment with once weekly semaglutide for diabetes. Journal of Diabetes & Metabolic Disorders.
Crossref
Crossref
Zhen Feng, Wai Kei Tong, Xinyue Zhang & Zhijia Tang. (2023) Cost-effectiveness analysis of once-daily oral semaglutide versus placebo and subcutaneous glucagon-like peptide-1 receptor agonists added to insulin in patients with type 2 diabetes in China. Frontiers in Pharmacology 14.
Crossref
Crossref
Tingting Wu, Carlos K H Wong, David T W Lui, Simon K H Wong, Cindy L K Lam, Matthew S H Chung, David A McAllister, Richard Welbourn & John B Dixon. (2023) Bariatric surgery, novel glucose-lowering agents, and insulin for type 2 diabetes and obesity: Bayesian network meta-analysis of randomized controlled trials. BJS Open 7:4.
Crossref
Crossref
Mahna Ekhlasi, Saeed Taheri & Nazila Yousefi. (2022) Cost-Effectiveness of Dulaglutide Versus Liraglutide for Management of Type 2 Diabetes Mellitus in Iran. Value in Health Regional Issues 32, pages 54-61.
Crossref
Crossref
Staffan Berg, Helena Edlund, William R. F. Goundry, Christel A. S. Bergström & Nigel M. Davies. (2022) Considerations in the developability of peptides for oral administration when formulated together with transient permeation enhancers. International Journal of Pharmaceutics 628, pages 122238.
Crossref
Crossref
Mengwei Li, Xiaowei Chi, Ying Wang, Sarra Setrerrahmane, Wenwei Xie & Hanmei Xu. (2022) Trends in insulin resistance: insights into mechanisms and therapeutic strategy. Signal Transduction and Targeted Therapy 7:1.
Crossref
Crossref
Shashank R. Joshi, Rajesh Rajput, Subhankar Chowdhury, Awadhesh K. Singh, Ganapathi Bantwal, Ashok K. Das, A.G. Unnikrishnan, Banshi D. Saboo, Jothydev Kesavadev, Samit Ghosal & Viswanathan Mohan. (2022) The role of oral semaglutide in managing type 2 diabetes in Indian clinical settings: Addressing the unmet needs. Diabetes & Metabolic Syndrome: Clinical Research & Reviews 16:6, pages 102508.
Crossref
Crossref
Björn Eliasson, Åsa Ericsson, Adam Fridhammar, Andreas Nilsson, Sofie Persson & Barrie Chubb. (2022) Long-Term Cost Effectiveness of Oral Semaglutide Versus Empagliflozin and Sitagliptin for the Treatment of Type 2 Diabetes in the Swedish Setting. PharmacoEconomics - Open 6:3, pages 343-354.
Crossref
Crossref
Nimer S. Alkhatib, Abdulaali R. Almutairi, Omar S. Alkhezi, Osama M. Alfayez, Majed S. Al Yami & Omar A. Almohammed. (2022) Economic analysis of glucagon like peptide-1 receptor agonists from the Saudi Arabia payer perspective. Saudi Pharmaceutical Journal 30:4, pages 433-439.
Crossref
Crossref
Awadhesh Kumar Singh, Ritu Singh & Anoop Misra. (2022) Oral semaglutide in type 2 diabetes mellitus: Comprehensive review, critical appraisal and clinical consideration of its use in India. Diabetes & Metabolic Syndrome: Clinical Research & Reviews 16:3, pages 102436.
Crossref
Crossref
Zaynab Ahmad Mouhammad, Rupali Vohra, Anna Horwitz, Anna-Sophie Thein, Jens Rovelt, Barbara Cvenkel, Pete A. Williams, Augusto Azuara-Blanco & Miriam Kolko. (2022) Glucagon-Like Peptide 1 Receptor Agonists – Potential Game Changers in the Treatment of Glaucoma?. Frontiers in Neuroscience 16.
Crossref
Crossref
Puneet Tyagi, Ruchit Trivedi, Sergei Pechenov, Chandresh Patel, Jefferson Revell, Sarah Wills, Yue Huang, Anton I. Rosenbaum & J. Anand Subramony. (2021) Targeted oral peptide delivery using multi-unit particulates: Drug and permeation enhancer layering approach. Journal of Controlled Release 338, pages 784-791.
Crossref
Crossref
Juris J. Meier. (2021) Efficacy of Semaglutide in a Subcutaneous and an Oral Formulation. Frontiers in Endocrinology 12.
Crossref
Crossref
Shanshan Hu, Xiaorong Su, Xun Deng & Yong Wang. (2021) Exploring the Appropriate Price of Semaglutide for Type 2 Diabetes Patients Based on Cost-Utility Analysis in China. Frontiers in Pharmacology 12.
Crossref
Crossref
Andreas Andersen, Filip Krag Knop & Tina Vilsbøll. (2021) A Pharmacological and Clinical Overview of Oral Semaglutide for the Treatment of Type 2 Diabetes. Drugs 81:9, pages 1003-1030.
Crossref
Crossref
Areti Sofogianni & Konstantinos Tziomalos. (2020) Oral Semaglutide, A New Option in the Management of Type 2 Diabetes Mellitus: A Narrative Review. Advances in Therapy 37:10, pages 4165-4174.
Crossref
Crossref
Sanjay Kalra & Rakesh Sahay. (2020) A Review on Semaglutide: An Oral Glucagon-Like Peptide 1 Receptor Agonist in Management of Type 2 Diabetes Mellitus. Diabetes Therapy 11:9, pages 1965-1982.
Crossref
Crossref